Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
22 hedge funds and large institutions have $8.96M invested in Checkpoint Therapeutics in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
63% more capital invested
Capital invested by funds: $5.5M → $8.96M (+$3.46M)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
16% more funds holding
Funds holding: 19 → 22 (+3)
0.03% less ownership
Funds ownership: 1.12% → 1.08% (-0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAS
Park Avenue Securities
New York
|
+$213K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$176K |
| 3 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$131K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$113K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$52.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BII
Bainco International Investors
Boston,
Massachusetts
|
-$157K |
| 2 |
FAM
Fenimore Asset Management
Cobleskill,
New York
|
-$128K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$36.6K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$24K |
| 5 |
BBL
Beck Bode LLC
Dedham,
Massachusetts
|
-$18K |
CKPT Hedge Fund Activity: Q1 2019 in Review
22 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q1 2019, worth a combined $8.96M — up 63% from $5.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CKPT positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Park Avenue Securities, opening a new position worth an estimated $213K. The largest seller was Bainco International Investors, cutting an estimated $157K.
- 22 institutional investors held Checkpoint Therapeutics (CKPT) as of Q1 2019, up from 19 in Q4 2018.
- Funds reported $8.96M of Checkpoint Therapeutics stock for Q1 2019, up 63% quarter-over-quarter.
- 6 funds opened new Checkpoint Therapeutics positions in Q1 2019 and 3 closed out, a net change of +3 holders.
- The largest Checkpoint Therapeutics buyer in Q1 2019 was Park Avenue Securities, an estimated $213K added.
- The largest Checkpoint Therapeutics seller in Q1 2019 was Bainco International Investors, an estimated $157K sold.
Based on aggregated 13F filings for Q1 2019.